PT-141 10mg
PT-141 (bremelanotide) is a synthetic cyclic peptide analog of α-melanocyte-stimulating hormone (α-MSH) and a melanocortin receptor agonist. It is primarily studied for its activity at MC3R and MC4R, with research focusing on melanocortin receptor pharmacology, peptide-receptor interactions, cAMP signaling, G-protein signaling, and structure–activity relationships.
Compound information
What is the Peptide?
A melanocortin peptide developed from Melanotan-II, refined to emphasize activity at the MC4R receptor rather than pigmentation. Also called bremelanotide, it is a brain-penetrant analog studied for central melanocortin signaling, and it stands as one of the more clinically characterized peptides in this family.
Structure
Stability information
Product overview
An MC4R-focused melanocortin research peptide supplied for laboratory evaluation at a ≥99% HPLC analytical standard.
Technical overview
PT-141 is a cyclic heptapeptide closely related to Melanotan-II, from which it was derived. The key structural difference is the loss of the C-terminal amide, which sharply reduces the pigmentation activity seen with its parent and shifts the emphasis toward MC4R signaling in the brain.
It is produced by solid-phase synthesis and preparative purification, then released against a lot-matched Certificate of Analysis carrying HPLC purity and LC-MS identity.
Research applications
PT-141 is used as a brain-penetrant melanocortin agonist for central-pathway research. Common laboratory work includes MC4R binding and cAMP-signaling assays in receptor-expressing cells, studies of melanocortin activity in hypothalamic and limbic brain regions, dopamine-release models, and receptor structure-activity research comparing it against its Melanotan-II parent.
Kylo Peptides supplies this compound as a reference material for scientific inquiry. All applications must be conducted by qualified professionals in controlled laboratory environments. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.
Frequently Researched Together
Frequently Asked Questions
PT-141 was built from Melanotan-II but changed in one important way: it lacks the C-terminal amide group its parent carries. That single difference greatly lowers the pigmentation activity associated with Melanotan-II and shifts PT-141's emphasis toward MC4R signaling, making it the more focused melanocortin tool of the two.
Because it can reach melanocortin receptors within the central nervous system. Much of the research interest in PT-141 centers on its activity at MC4R in hypothalamic and limbic brain regions, which is why it is studied for central melanocortin pathways rather than only peripheral pigment cells.
Yes, they are the same peptide. Bremelanotide is the generic name and PT-141 the research designation. The compound has been studied clinically and carries an FDA-approved status for a specific medical indication under a brand name, though the material offered here is research-grade for laboratory use only.
Analysis places every lot at ≥99% by HPLC, with mass spectrometry confirming its identity. Each batch clears independent third-party testing before it leaves, and you can retrieve the certificate for your lot using the number printed on the vial.
Frozen and dry. Keep the lyophilized powder at −20 °C, sealed and out of light, using −80 °C for longer storage. Once reconstituted, hold the solution at 2 to 8 °C, work through it within a validated window, and avoid cycling it between frozen and thawed.
No. Kylo supplies PT-141 as a characterized reagent for in vitro laboratory research only. It is not formulated or labeled for use in humans or animals, is not a substitute for the approved drug product, and is provided strictly to qualified researchers.
Backed By A Lot-Matched COA
Every PT-141 order is tied to a certificate of analysis matched to the exact lot in your vial.
Shop catalog →
